GuruFocus Premium Membership

Serving Intelligent Investors since 2004. Only 96 cents a day.

Free Trial

Free 7-day Trial
All Articles and Columns »

David Einhorn Increases Position in CareFusion Corp. by 33%

August 16, 2011 | About:
hyperman299

hyperman299

4 followers
David Einhorn increased his position in CareFusion Corp. (CFN) by 33% at the average price of $24.76 on 08/15/2011, as reported in the latest 13G filings by David Einhorn. He owns 12,668,724 shares. CareFusion is a global corporation serving the health care industry with products and services that help hospitals measurably improve the safety and quality of care. CareFusion Corp. has a market cap of $5.72 billion; its shares were traded at around $24.76 with a P/E ratio of 15.23 and P/S ratio of 1.62.

Andreas Halvorsen bought 1,934,612 shares in the quarter that ended on 03/31/2011, which is 0.47% of the $11.95 billion portfolio of Viking Global Investors LP. John Keeley owns 188,290 shares as of 06/30/2011, an increase of 23.69% from the previous quarter. This position accounts for 0.0835% of the $6.13 billion portfolio of Keeley Fund Management. Edward Owens owns 4,284,654 shares as of 06/30/2011, an increase of 20.07% from the previous quarter. This position accounts for 0.5852% of the $19.89 billion portfolio of Vanguard Health Care Fund. George Soros owns 9,200 shares as of 06/30/2011, a decrease of 67.03% of from the previous quarter. This position accounts for 0.0035% of the $7.11 billion portfolio of Soros Fund Management LLC.

CareFusion recently reported its fourth quarter and fiscal 2011 results. Revenue for the fourth quarter of fiscal 2011 increased 4% to $964 million on a reported basis and 2% on a constant currency basis, driven primarily by increased sales in the Infusion, Dispensing and Infection Prevention businesses. Operating income was $149 million and income from continuing operations was $96 million, or $0.42 per diluted share.

"Growth in our Infusion, Dispensing and Infection Prevention businesses, gross margin expansion and the benefit of strong spending controls drove double digit improvements in our adjusted operating earnings for the quarter and for the year," said Kieran Gallahue, chairman and CEO. "We continue to make progress in optimizing our product portfolio and expanding our geographical footprint. We recently acquired pharmacy automation innovator Rowa, enabling us to expand our Pyxis platform outside the U.S."


Rating: 2.3/5 (6 votes)

Comments

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK